Nicotine consumption during the prodromal phase of schizophrenia – a review of the literature

References

• Szatkowski L, McNeill A. Diverging trends in smoking behaviors according to mental health status. Nicotine Tob Res. 2015. doi:10.1093/ntr/ntu173
   Web of Science ®Google Scholar
• Mendelsohn CP, Kirby DP, Castle DJ. Smoking and mental illness. An update for psychiatrists. Australas Psychiatry. 2015. doi:10.1177/1039856214562076
   Web of Science ®Google Scholar
• Lê Cook B, Wayne GF, Kafali EN, Liu Z, Shu C, Flores M. Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. JAMA. 2014. doi:10.1001/jama.2013.284985
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Vital signs: current cigarette smoking among adults aged ≥18 years with mental illness - United States, 2009–2011. MMWR Morb Mortal Wkly Rep 2013;62(5):81–87.
   Google Scholar
• Prochaska JJ, Das S, Young-Wolff KC. Smoking, Mental Illness, and Public Health. Annu Rev Public Health 2017;38(1):165–185. doi:10.1146/annurev-publhealth-031816-044618
   Google Scholar
• Hartz SM, Pato CN, Medeiros H, et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry. 2014. doi:10.1001/jamapsychiatry.2013.3726
   Web of Science ®Google Scholar
• Dickerson F, Schroeder J, Katsafanas E, et al. Cigarette smoking by patients with serious mental illness, 1999–2016: an increasing disparity. Psychiatr Serv. 2017. doi:10.1176/appi.ps.201700118
   Web of Science ®Google Scholar
• Dickerson F, Stallings CR, Origoni AE, et al. Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999–2011. Psychiatr Serv. 2013. doi:10.1176/appi.ps.201200143
   Web of Science ®Google Scholar
• Parikh V, Kutlu MG, Gould TJ. nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: current trends and perspectives. Schizophr Res. 2016;171(1–3):1–15. doi:10.1016/j.schres.2016.01.02026803692
   PubMed Web of Science ®Google Scholar
• Gage SH, Munafò MR. Rethinking the association between smoking and schizophrenia. Lancet Psychiatry. 2015;2(2):118–119. doi:10.1016/s2215-0366(14)00057-126359739
   PubMed Web of Science ®Google Scholar
• Anderson SM, Brunzell DH. Anxiolytic-like and anxiogenic-like effects of nicotine are regulated via diverse action at β2-nicotinic acetylcholine receptors. Br J Pharmacol. 2015. doi:10.1111/bph.13090
   Web of Science ®Google Scholar
• Picciotto MR, Lewis AS, van Schalkwyk GI, Mineur YS. Mood and anxiety regulation by nicotinic acetylcholine receptors: a potential pathway to modulate aggression and related behavioral states. Neuropharmacology. 2015;96:235–243. doi:10.1016/j.neuropharm.2014.12.02825582289
   PubMed Web of Science ®Google Scholar
• Kutlu MG, Parikh V, Gould TJ. Nicotine addiction and psychiatric disorders. Int Rev Neurobiol. 2015;124:171–208. doi:10.1016/bs.irn.2015.08.00426472530
   PubMed Web of Science ®Google Scholar
• Domino EF, Mirzoyan D, Tsukada H. N-methyl-d-aspartate antagonists as drug models of schizophrenia: a surprising link to tobacco smoking. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(5):801–811. doi:10.1016/j.pnpbp.2004.05.02415363604
   PubMed Web of Science ®Google Scholar
• Levin ED, Petro A, Caldwell DP. Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-d-aspartate (NMDA) glutamatergic receptor blockade. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(4):581–586. doi:10.1016/j.pnpbp.2005.01.01215866361
   PubMed Web of Science ®Google Scholar
• Tamminga CA, Buchanan RW, Gold JM. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol. 1998. doi:10.1097/00004850-199803003-00004
   Web of Science ®Google Scholar
• Sandyk R. Cigarette smoking: effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia. Int J Neurosci. 1993;70(3–4):193–197. doi:10.3109/002074593090005748063538
   PubMed Web of Science ®Google Scholar
• Decina P, Caracci G, Sandik R, Berman W, Mukherjee S, Scapicchio P. Cigarette smoking and neuroleptic-induced parkinsonism. Biol Psychiatry. 1990;28(6):502–508. doi:10.1016/0006-3223(90)90483-i1977478
   PubMed Web of Science ®Google Scholar
• Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotrophic medications: a pharmacokinetic perspective. CNS Drugs. 2001. doi:10.2165/00023210-200115060-00005
   Web of Science ®Google Scholar
• Pomerleau OF, Rosecrans J. Neuroregulatory effects of nicotine. Psychoneuroendocrinology. 1989;14(6):407–423. doi:10.1016/0306-4530(89)90040-12560221
   PubMed Web of Science ®Google Scholar
• Azaiez C, Millier A, Lançon C, et al. Health related quality of life in patients having schizophrenia negative symptoms – a systematic review. J Mark Access Heal Policy. 2018;6(1):1517573. doi:10.1080/20016689.2018.1517573
   PubMedGoogle Scholar
• Sakurai H, Bies RR, Stroup ST, et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull. 2012;39(3):564–574. doi:10.1093/schbul/sbr18922290266
   PubMed Web of Science ®Google Scholar
• Hu W, MacDonald ML, Elswick DE, Sweet RA. The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann NY Acad Sci. 2014;1338(1):38–57. doi:10.1111/nyas.1254725315318
   PubMed Web of Science ®Google Scholar
• Selvaraj S, Arnone D, Cappai A, Howes O. Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci Biobehav Rev. 2014;45:233–245. doi:10.1016/j.neubiorev.2014.06.00524971825
   PubMed Web of Science ®Google Scholar
• Steeds H, Carhart-Harris RL, Stone JM. Drug models of schizophrenia. Ther Adv Psychopharmacol. 2014;5(1):43–58. doi:10.1177/2045125314557797
   Google Scholar
• Ripoll N, Bronnec M, Bourin M. Nicotinic receptors and schizophrenia. Curr Med Res Opin. 2004;20(7):1057–1074. doi:10.1185/03007990412500406015265251
   PubMed Web of Science ®Google Scholar
• Scarr E, Gibbons AS, Neo J, Udawela M, Dean B. Cholinergic connectivity: it’s implications for psychiatric disorders. Front Cell Neurosci. 2013;7. doi:10.3389/fncel.2013.00055
   Web of Science ®Google Scholar
• Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry. 2003;36(S03):162–167. doi:10.1055/s-2003-45125
   Google Scholar
• Gourzis P, Katrivanou A, Beratis S. Symptomatology of the initial prodomal phase in schizophrenia. Schizophr Bull. 2002. doi:10.1093/oxfordjournals.schbul.a006950
   Web of Science ®Google Scholar
• Löffler W, Häfner H. [Long prodromal phase in schizophrenia. By recognizing it, the prognosis of the patient can be significantly improved]. MMW Fortschr Med 2000;142(10):26–29. German.
   Google Scholar
• Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, et al. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry. 2015. doi:10.1016/j.eurpsy.2015.01.013
   Web of Science ®Google Scholar
• Cannon TD. How schizophrenia develops: cognitive and brain mechanisms underlying onset of psychosis. Trends Cogn Sci. 2015. doi:10.1016/j.tics.2015.09.009
   Web of Science ®Google Scholar
• Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703–715. doi:10.1093/oxfordjournals.schbul.a00704014989408
   PubMed Web of Science ®Google Scholar
• McGorry PD, Nelson B, Phillips LJ, et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry. 2013. doi:10.4088/JCP.12m07785
   Web of Science ®Google Scholar
• Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull. 2009. doi:10.1093/schbul/sbn139
   Web of Science ®Google Scholar
• Klosterkötter J, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Schizophr Res. 2000;41(1):10–11. doi:10.1016/s0920-9964(00)90330-x
   Web of Science ®Google Scholar
• Rosen J, Miller T, Dandrea J, Mcglashan T, Woods S. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr Res. 2006;85(1–3):124–131. doi:10.1016/j.schres.2006.03.03416650735
   PubMed Web of Science ®Google Scholar
• Kalkman HO, Feuerbach D. Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders. Cell Mol Life Sci. 2016. doi:10.1007/s00018-016-2175-4
   Web of Science ®Google Scholar
• Yu R, Deochand C, Krotow A, et al. Tobacco smoke-induced brain white matter myelin dysfunction: potential co-factor role of smoking in neurodegeneration. J Alzheimer’s Dis. 2015. doi:10.3233/JAD-150751
   Web of Science ®Google Scholar
• Lin F, Wu G, Zhu L, Lei H. Heavy smokers show abnormal microstructural integrity in the anterior corpus callosum: a diffusion tensor imaging study with tract-based spatial statistics. Drug Alcohol Depend. 2013. doi:10.1016/j.drugalcdep.2012.09.013
   Web of Science ®Google Scholar
• Kelly C, McCreadie RG. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 1999;156(11):1751–1757.
   Google Scholar
• Beratis S, Katrivanou A, Gourzis P. Factors affecting smoking in schizophrenia. Compr Psychiatry. 2001;42(5):393–402. doi:10.1053/comp.2001.2627311559866
   PubMed Web of Science ®Google Scholar
• Sandyk R, Kay SR. Brief communication: tobacco addiction as a marker of age at onset of schizophrenia. Int J Neurosci. 1991;57(3–4):259–262. doi:10.3109/002074591091506991938168
   PubMed Web of Science ®Google Scholar
• Weiser M, Reichenberg A, Grotto I, et al. Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am J Psychiatry. 2004;161(7):1219–1223. doi:10.1176/appi.ajp.161.7.121915229054
   PubMed Web of Science ®Google Scholar
• Üneri Ö, Tural Ü, Çakin Memik N. Smoking and schizophrenia: where is the biological connection? Turk Psikiyatr Derg. 2006;17(1):1–10.
   Web of Science ®Google Scholar
• Zammit S, Allebeck P, Dalman C, Lundberg I, Hemmingsson T, Lewis G. Investigating the association between cigarette smoking and schizophrenia in a cohort study. Am J Psychiatry. 2003;160(12):2216–2221. doi:10.1176/appi.ajp.160.12.221614638593
   PubMed Web of Science ®Google Scholar
• Kendler KS, Lönn SL, Sundquist J, Sundquist K. Smoking and schizophrenia in population cohorts of Swedish women and men: a prospective co-relative control study. Am J Psychiatry. 2015;172(11):1092–1100. doi:10.1176/appi.ajp.2015.1501012626046339
   PubMed Web of Science ®Google Scholar
• Gurillo P, Jauhar S, Murray RM, MacCabe JH. Does tobacco use cause psychosis? Systematic review and meta-analysis. Lancet Psychiatry. 2015;2(8):718–725. doi:10.1016/s2215-0366(15)00152-226249303
   PubMed Web of Science ®Google Scholar
• de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2–3):135–157. doi:10.1016/j.schres.2005.02.01015949648
   PubMed Web of Science ®Google Scholar
• Riala K, Hakko H, Isohanni M, Pouta A, Räsänen P. Is initiation of smoking associated with the prodromal phase of schizophrenia? J Psychiatry Neurosci 2005;30(1):26–32.
   Google Scholar
• Zhang XY, Liang J, Chen DC, et al. Cigarette smoking in male patients with chronic schizophrenia in a Chinese population: prevalence and relationship to clinical phenotypes. PLoS One. 2012;7(2):e30937. doi:10.1371/journal.pone.003093722347412
   PubMed Web of Science ®Google Scholar
• Diaz FJ, Velásquez DM, Susce MT, de Leon J. The association between schizophrenia and smoking: unexplained by either the illness or the prodromal period. Schizophr Res. 2008;104(1–3):214–219. doi:10.1016/j.schres.2008.06.00418650069
   PubMed Web of Science ®Google Scholar
• Cadenhead KS. Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population. Psychiatry Res. 2011;188(2):208–216. doi:10.1016/j.psychres.2011.04.01121555157
   PubMed Web of Science ®Google Scholar
• Gupta T, Mittal VA. Nicotine usage is associated with elevated processing speed, spatial working memory, and visual learning performance in youth at ultrahigh-risk for psychosis. Psychiatry Res. 2014;220(1–2):687–690. doi:10.1016/j.psychres.2014.07.08525190344
   PubMed Web of Science ®Google Scholar
• Buchy L, Perkins D, Woods SW, Liu L, Addington J. Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosis. Schizophr Res. 2014. doi:10.1016/j.schres.2014.04.021
   Web of Science ®Google Scholar
• Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res. 2007. doi:10.1016/j.psychres.2006.10.001
   Web of Science ®Google Scholar
• Compton MT, Kelley ME, Ramsay CE, et al. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am J Psychiatry. 2009. doi:10.1176/appi.ajp.2009.09030311
   Web of Science ®Google Scholar
• Bora E, Yalincetin B, Akdede BB, Alptekin K. Duration of untreated psychosis and neurocognition in first-episode psychosis: a meta-analysis. Schizophr Res. 2018. doi:10.1016/j.schres.2017.06.021
   Web of Science ®Google Scholar
• Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011. doi:10.1001/archgenpsychiatry.2011.5
   Web of Science ®Google Scholar
• Stewart DW, Vinci C, Adams CE, Cohen AS, Copeland AL. Smoking topography and outcome expectancies among individuals with schizotypy. Psychiatry Res. 2013;205(3):205–212. doi:10.1016/j.psychres.2012.11.03223261186
   PubMed Web of Science ®Google Scholar
• Kulhara P, Gupta S. What is schizophrenia: a neurodevelopmental or neurodegenerative disorder or a combination of both? A critical analysis. Indian J Psychiatry. 2010;52(1):21. doi:10.4103/0019-5545.5889120174514
   PubMedGoogle Scholar
• Carney R, Cotter J, Bradshaw T, Firth J, Yung AR. Cardiometabolic risk factors in young people at ultra-high risk for psychosis: a systematic review and meta-analysis. Schizophr Res. 2016;170(2–3):290–300. doi:10.1016/j.schres.2016.01.01026794596
   PubMed Web of Science ®Google Scholar
• Roberts E, Eden Evins A, Mcneill A, Robson D. Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis. Addiction. 2016. doi:10.1111/add.13236
   Web of Science ®Google Scholar
• Tidey JW, Miller ME. Smoking cessation and reduction in people with chronic mental illness. BMJ. 2015;h4065. doi:10.1136/bmj.h406526391240
   PubMed Web of Science ®Google Scholar
• Myles N, Newall HD, Curtis J, Nielssen O, Shiers D, Large M. Tobacco use before, at, and after first-episode psychosis. J Clin Psychiatry. 2012;73(04):468–475. doi:10.4088/jcp.11r0722222579146
   PubMed Web of Science ®Google Scholar
• Skokou M, Gourzis P. Demographic features and premorbid personality disorder traits in relation to age of onset and sex in paranoid schizophrenia. Psychiatry Res. 2014. doi:10.1016/j.psychres.2014.01.018
   Web of Science ®Google Scholar
• Beratis S, Gabriel J, Hoidas S. Age at onset in subtypes of schizophrenic disorders. Schizophr Bull. 1994. doi:10.1093/schbul/20.2.287
   Web of Science ®Google Scholar
• Skokou M, Katrivanou A, Andriopoulos I, Gourzis P. Active and prodromal phase symptomatology of young-onset and late-onset paranoid schizophrenia. Rev Psiquiatr y Salud Ment. 2012. doi:10.1016/j.rpsmen.2012.03.002
   Web of Science ®Google Scholar
• Terry Alvin J. Role of the central cholinergic system in the therapeutics of schizophrenia. Curr Neuropharmacol. 2008;6(3):286–292. doi:10.2174/15701590878577724719506725
   PubMed Web of Science ®Google Scholar
• Heilbronner U, Samara M, Leucht S, Falkai P, Schulze TG. The longitudinal course of schizophrenia across the lifespan. Harv Rev Psychiatry. 2016;24(2):118–128. doi:10.1097/hrp.000000000000009226954596
   PubMed Web of Science ®Google Scholar
• Manzella F. Smoking in schizophrenic patients: a critique of the self-medication hypothesis. World J Psychiatry. 2015;5(1):35. doi:10.5498/wjp.v5.i1.3525815253
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Nelson B, Valmaggia L, Yung AR, McGuire PK. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull. 2014. doi:10.1093/schbul/sbs136
   Web of Science ®Google Scholar
• Ripke S, Neale BM, Corvin A, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014. doi:10.1038/nature13595
   Web of Science ®Google Scholar
• Gage SH, Munafò MR. Smoking as a causal risk factor for schizophrenia. Lancet Psychiatry. 2015;2(9):778–779. doi:10.1016/s2215-0366(15)00333-826236007
   PubMed Web of Science ®Google Scholar
• Flint J, Munafò M. Genesis of a complex disease. Nature. 2014;511(7510):412–413. doi:10.1038/nature1364525056056
   PubMed Web of Science ®Google Scholar
• Furberg H, Kim Y, Dackor J, et al. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet. 2010;42(5):441–447. doi:10.1038/ng.57120418890
   PubMed Web of Science ®Google Scholar
• De Luca V, Wong AHC, Muller DJ, Wong GWH, Tyndale RF, Kennedy JL. Evidence of association between smoking and α7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology. 2004;29(8):1522–1526. doi:10.1038/sj.npp.130046615100704
   PubMed Web of Science ®Google Scholar
• Saccone NL, Schwantes-An T-H, Wang JC, et al. Multiple cholinergic nicotinic receptor genes affect nicotine dependence risk in African and European Americans. Genes Brain Behav. 2010;9(7):741–750. doi:10.1111/j.1601-183x.2010.00608.x20584212
   PubMed Web of Science ®Google Scholar
• Gage SH, Jones HJ, Taylor AE, Burgess S, Zammit S, Munafò MR. Investigating causality in associations between smoking initiation and schizophrenia using Mendelian randomization. Sci Rep. 2017;7(1):40653. doi:10.1038/srep4065328102331
   PubMed Web of Science ®Google Scholar
• Chen J, Bacanu SA, Yu H, et al. Genetic relationship between schizophrenia and nicotine dependence. Sci Rep. 2016. doi:10.1038/srep25671
   Web of Science ®Google Scholar
• Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018. doi:10.1136/bmj.k601
   Web of Science ®Google Scholar
• Wootton RE, Richmond RC, Stuijfzand BG, et al. Causal effects of lifetime smoking on risk for depression and schizophrenia: evidence from a Mendelian randomisation study. bioRxiv. 2018. doi:10.1101/381301
   Google Scholar
• Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull. 2009;35(3):549–562. doi:10.1093/schbul/sbp00619325164
   PubMed Web of Science ®Google Scholar
• Novak G, Seeman P, Foll BL. Exposure to nicotine produces an increase in dopamine D2HighReceptors: a possible mechanism for dopamine hypersensitivity. Int J Neurosci. 2010;120(11):691–697. doi:10.3109/00207454.2010.51346220942582
   PubMed Web of Science ®Google Scholar
• Aosaki T, Miura M, Suzuki T, Nishimura K, Masuda M. Acetylcholine-dopamine balance hypothesis in the striatum: an update. Geriatr Gerontol Int. 2010;10:S148–S157. doi:10.1111/j.1447-0594.2010.00588.x20590830
   PubMed Web of Science ®Google Scholar
• Higley MJ, Picciotto MR. Neuromodulation by acetylcholine: examples from schizophrenia and depression. Curr Opin Neurobiol. 2014;29:88–95. doi:10.1016/j.conb.2014.06.00424983212
   PubMed Web of Science ®Google Scholar
• Margolese HC, Carlos Negrete J, Tempier R, Gill K. A 12-month prospective follow-up study of patients with schizophrenia-spectrum disorders and substance abuse: changes in psychiatric symptoms and substance use. Schizophr Res. 2006. doi:10.1016/j.schres.2005.11.019
   Web of Science ®Google Scholar
• de Leon J. Psychopharmacology: atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv. 2004. doi:10.1176/appi.ps.55.5.491
   Web of Science ®Google Scholar
• Sullivan G, Wells KB, Morgenstern H, Leake B. Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry. 1995. doi:10.1176/ajp.152.12.1749
   Web of Science ®Google Scholar
• Warner R, Taylor D, Wright J, et al. Substance use among the mentally ILL: prevalence, reasons for use, and effects on illness. Am J Orthopsychiatry. 1994. doi:10.1037/h0079489
   Web of Science ®Google Scholar